Incyte Co. (NASDAQ:INCY) Shares Purchased by SG Americas Securities LLC

SG Americas Securities LLC lifted its position in Incyte Co. (NASDAQ:INCY) by 262.2% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 99,407 shares of the biopharmaceutical company’s stock after acquiring an additional 71,963 shares during the quarter. SG Americas Securities LLC’s holdings in Incyte were worth $6,866,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Point72 Asset Management L.P. bought a new position in shares of Incyte in the 3rd quarter worth about $156,611,000. Mizuho Securities USA LLC raised its position in shares of Incyte by 13,814.7% during the 3rd quarter. Mizuho Securities USA LLC now owns 2,000,100 shares of the biopharmaceutical company’s stock worth $132,207,000 after buying an additional 1,985,726 shares in the last quarter. Teachers Retirement System of The State of Kentucky boosted its holdings in shares of Incyte by 2,486.8% in the second quarter. Teachers Retirement System of The State of Kentucky now owns 394,646 shares of the biopharmaceutical company’s stock valued at $23,923,000 after acquiring an additional 379,390 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in shares of Incyte by 29.2% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,609,220 shares of the biopharmaceutical company’s stock valued at $106,369,000 after acquiring an additional 364,169 shares during the period. Finally, Dimensional Fund Advisors LP raised its holdings in Incyte by 24.3% during the second quarter. Dimensional Fund Advisors LP now owns 1,181,269 shares of the biopharmaceutical company’s stock worth $71,617,000 after purchasing an additional 230,665 shares in the last quarter. 96.97% of the stock is currently owned by institutional investors.

Incyte Stock Performance

INCY stock opened at $72.59 on Friday. The company has a market capitalization of $13.98 billion, a price-to-earnings ratio of 518.54, a P/E/G ratio of 0.53 and a beta of 0.71. The firm has a 50 day moving average of $71.76 and a two-hundred day moving average of $68.33. The company has a quick ratio of 1.82, a current ratio of 1.87 and a debt-to-equity ratio of 0.01. Incyte Co. has a 12 month low of $50.35 and a 12 month high of $83.95.

Incyte (NASDAQ:INCY) last posted its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.07 EPS for the quarter, missing the consensus estimate of $1.19 by ($0.12). Incyte had a negative return on equity of 0.63% and a net margin of 0.80%. The business had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.08 billion. During the same period in the previous year, the company earned $0.91 earnings per share. The company’s quarterly revenue was up 23.8% compared to the same quarter last year. As a group, equities analysts anticipate that Incyte Co. will post 0.39 EPS for the current fiscal year.

Analyst Ratings Changes

INCY has been the topic of several research analyst reports. UBS Group assumed coverage on Incyte in a research report on Tuesday, December 17th. They set a “neutral” rating and a $77.00 price target on the stock. StockNews.com cut shares of Incyte from a “strong-buy” rating to a “buy” rating in a research report on Friday, December 13th. Cantor Fitzgerald restated a “neutral” rating on shares of Incyte in a research report on Friday, January 10th. BMO Capital Markets reiterated an “underperform” rating and issued a $52.00 target price (up from $48.00) on shares of Incyte in a report on Wednesday, October 30th. Finally, Morgan Stanley raised their target price on shares of Incyte from $64.00 to $69.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 30th. One analyst has rated the stock with a sell rating, eleven have given a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $75.71.

Insider Activity at Incyte

In other Incyte news, EVP Steven H. Stein sold 12,352 shares of the company’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $72.69, for a total transaction of $897,866.88. Following the completion of the sale, the executive vice president now directly owns 66,967 shares in the company, valued at $4,867,831.23. This represents a 15.57 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Vijay K. Iyengar sold 6,043 shares of Incyte stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $75.38, for a total value of $455,521.34. Following the completion of the transaction, the executive vice president now owns 30,658 shares in the company, valued at $2,311,000.04. The trade was a 16.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 23,375 shares of company stock valued at $1,737,578. Corporate insiders own 17.60% of the company’s stock.

Incyte Company Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.